Fortress Biotech, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

License Agreements (R&D and Journey) (Details)

License Agreements (R&D and Journey) (Details) ¥ in Billions			1 Months Ended								3 Months Ended	12 Months Ended
	Jan. 02, 2025 USD ($)	Aug. 31, 2023 USD ($)	Dec. 31, 2024 USD ($)	Apr. 30, 2024 USD ($)	Aug. 31, 2023 USD ($)	Aug. 31, 2023 JPY (¥)	Jan. 31, 2022 USD ($) agreement	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jul. 31, 2020 USD ($) item	Dec. 31, 2025 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Nov. 11, 2024 USD ($)
License Agreements
Expense recognized for licenses acquired												$ 0	$ 300,000
Revenues												63,262,000	57,675,000
Other revenue												2,023,000	$ 1,000,000
VYNE Product Acquisition
License Agreements
Deferred cash payment							$ 5,000,000
VYNE Product Acquisition
License Agreements
Number of products agreed to be acquired under license agreement \| agreement							2
Cash payments							$ 20,000,000
Journey
License Agreements
Payments of milestones											$ 15,000,000
Journey \| VYNE Product Acquisition
License Agreements
Sales-based milestone payments paid and payable to date														$ 1,000,000
Journey \| Emrosi Agreement
License Agreements
Upfront fees paid								$ 10,000,000
Milestone paid			$ 15,000,000	$ 3,000,000
Percentage reduction in royalty payment percentage upon launch of generic competitor								50.00%
Journey \| Qbexza Asset Purchase
License Agreements
Upfront fees paid									$ 12,500,000
Journey \| Qbexza, License Agreement
License Agreements
Aggregate milestone payments receivable		$ 45,000,000
Net sales \| ¥						¥ 4
Revenues					$ 19,000,000
Possible reduction in milestone payments receivable		$ 10,000,000
Journey \| Accutane
License Agreements
Upfront fees paid										$ 5,000,000
Sales milestone payable										$ 17,000,000
Agreement term										10 years
Termination notice period										180 days
Number of sales milestones \| item										3
Journey \| Vyne Asset Purchase \| Cutia Therapeutics (HK) Limited
License Agreements
Cash payments from Cutia	$ 1,000,000
Other revenue												$ 600,000
Minimum \| Journey \| Emrosi Agreement
License Agreements
Percentage of royalty on future net sales								10.00%
Maximum \| VYNE Product Acquisition
License Agreements
Sales-based milestone payments paid and payable to date							450,000,000
Maximum \| Journey \| Emrosi Agreement
License Agreements
Additional milestones payable								$ 150,000,000
Percentage of royalty on future net sales								14.00%
Maximum \| Journey \| Qbexza Asset Purchase
License Agreements
Additional milestones payable									$ 144,000,000
First Specified Period Or Condition [Member] \| Journey \| Qbexza Asset Purchase
License Agreements
Royalty period									2 years
First Specified Period Or Condition [Member] \| Minimum \| Journey \| Qbexza Asset Purchase
License Agreements
Percentage of royalty on future net sales									30.00%
First Specified Period Or Condition [Member] \| Maximum \| Journey \| Qbexza Asset Purchase
License Agreements
Percentage of royalty on future net sales									40.00%
Second Specified Period Or Condition [Member] \| Journey \| Qbexza Asset Purchase
License Agreements
Royalty period									8 years
Second Specified Period Or Condition [Member] \| Minimum \| Journey \| Qbexza Asset Purchase
License Agreements
Percentage of royalty on future net sales									12.00%
Second Specified Period Or Condition [Member] \| Maximum \| Journey \| Qbexza Asset Purchase
License Agreements
Percentage of royalty on future net sales									19.00%
Annual Sales Of $100 Million \| VYNE Product Acquisition
License Agreements
Revenues							100,000,000
Sales-based milestone payments paid and payable to date							10,000,000
Annual Sales Of $200 Million \| VYNE Product Acquisition
License Agreements
Revenues							200,000,000
Sales-based milestone payments paid and payable to date							20,000,000
Annual Sales Of $300 Million \| VYNE Product Acquisition
License Agreements
Revenues							300,000,000
Sales-based milestone payments paid and payable to date							30,000,000
Annual Sales Of $400 Million \| VYNE Product Acquisition
License Agreements
Revenues							400,000,000
Sales-based milestone payments paid and payable to date							40,000,000
Annual Sales Of $500 Million \| VYNE Product Acquisition
License Agreements
Revenues							500,000,000
Sales-based milestone payments paid and payable to date							$ 50,000,000